Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain

被引：27

作者：

Vazquez, Marta ^{[1
]}

Guevara, Natalia ^{[1
]}

Maldonado, Cecilia ^{[1
]}

Guido, Paulo Caceres ^{[2
]}

Schaiquevich, Paula ^{[3
,4
]}

机构：

[1] Univ Republica, Fac Quim, Dept Ciencias Farmaceut, Montevideo, Uruguay

[2] Hosp Pediat JP Garrahan, Unidad Farmacocinet Clin, Farm, Buenos Aires, DF, Argentina

[3] Hosp Pediat JP Garrahan, Med Precis, Buenos Aires, DF, Argentina

[4] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina

来源：

BIOMED RESEARCH INTERNATIONAL | 2020年 / 2020卷

关键词：

SEROTONIN REUPTAKE INHIBITORS; P-GLYCOPROTEIN INHIBITION; BLOOD-BRAIN-BARRIER; VALPROIC ACID; IN-VITRO; NEUROPATHIC PAIN; HUMAN LIVER; CANNABIDIOL; METABOLISM; VENLAFAXINE;

D O I：

10.1155/2020/3902740

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Choosing an appropriate treatment for chronic pain remains problematic, and despite the available medication for its treatment, still, many patients complain about pain and appeal to the use of cannabis derivatives for pain control. However, few data have been provided to clinicians about the pharmacokinetic drug-drug interactions of cannabinoids with other concomitant administered medications. Therefore, the aim of this brief review is to assess the interactions between cannabinoids and pain medication through drug transporters (ATP-binding cassette superfamily members) and/or metabolizing enzymes (cytochromes P450 and glucuronyl transferases).

引用

下载

页数：9

共 50 条

[41] Predictions of pharmacokinetic drug-drug interactions in a suicide population
Kosunen, Suvi
Sajantila, Antti
Niemi, Mikko
Filppula, Anne M.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2023, 132 : 12 - 13
[42] Drug-drug interactions with protein kinase inhibitors used in chronic myeloid leukemia
Falcou, L.
Pajiep, M.
Despas, F.
Conte, C.
Lapeyre-Mestre, M.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 59 - 60
[43] Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs
Voll, Marsha L.
Yap, Kim D.
Terpstra, Wim E.
Crul, Mirjam
PHARMACY WORLD & SCIENCE, 2010, 32 (05): : 575 - 580
[44] PHARMACOKINETIC DRUG-INTERACTIONS OF COMMONLY USED ANTICANCER DRUGS
BALIS, FM
CLINICAL PHARMACOKINETICS, 1986, 11 (03) : 223 - 235
[45] Prevalence of potential drug-drug interactions in outpatients on treatment with parenteral antineoplastic drugs
Castro-Manzanares, M.
do Pazo-Oubina, F.
Rodriguez-Rincon, R. M.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (06) : 1429 - 1433
[46] Drug-Drug Interactions Involving Pain Medications
Lisi, Donna M.
US PHARMACIST, 2014, 39 (03) : 65 - 74
[47] METABOLIC TRANSFORMATION OF CLINICALLY USED DRUGS TO EPOXIDES - NEW PERSPECTIVES IN DRUG-DRUG INTERACTIONS
OESCH, F
BIOCHEMICAL PHARMACOLOGY, 1976, 25 (17) : 1935 - 1937
[48] Transporter mediated uptake and efflux of antiretroviral drugs: Potential for drug-drug interactions
Riches, Zoe
Cameron, Gary A.
Hawksworth, Gabrielle M.
TOXICOLOGY, 2011, 290 (2-3) : 127 - 128
[49] Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters
Yamazaki, Shinji
JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (08): : 1053 - 1060
[50] EVALUATION OF POTENTIAL DRUG-DRUG INTERACTIONS BETWEEN BEVIRIMAT AND RALTEGRAVIR IN VITRO
Bullock, P. L.
Han, M. S.
Martin, D. E.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 : S82 - S82

← 1 2 3 4 5 →